What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2026-02-19 compared with 2025-02-20 · 45 added, 33 removed, 13 unchanged (86% of the section changed)

3 unchanged sentences

These matters are subject to many uncertainties and outcomes that are not predictable.

On February 6, 2024, a putative class action lawsuit was filed in the United States District Court for the Northern District of California alleging that we and our current Chief Executive Officer, Quentin Blackford, our former Chief Financial Officer, Brice Bobzien, and our former Chief Financial Officer and former Chief Operating Officer, Mr.

Devine violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 promulgated thereunder, and seeks unspecified damages purportedly sustained by the class.

On July 19, 2024, an amended complaint was filed, naming us, Mr.

On February 6, 2024, a putative class action lawsuit was filed in the United States District Court for the Northern District of California alleging that our wholly-owned subsidiary, iRhythm Technologies, and our current Chief Executive Officer, Quentin Blackford, iRhythm Technologies' former Chief Financial Officer, Brice Bobzien, and its former Chief Financial Officer and former Chief Operating Officer, Douglas Devine violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 promulgated thereunder, and seeks unspecified damages purportedly sustained by the class.

On July 19, 2024, an amended complaint was filed, naming iRhythm Technologies, Mr.

Blackford, Mr.

Devine, our Chief Commercial Officer Chad Patterson, our former Chief Technology Officer Mark Day, and our Chief Medical Officer, Chief Scientific Officer, and Executive Vice President of Product Innovation Mintu Turakhia as defendants.

On October 7, 2024, a second amended complaint was filed to include events from the recent FDA inspections, but otherwise included the same claims under the Exchange Act.

Devine, our Chief Commercial and Product Officer Chad Patterson, iRhythm Technologies' former Chief Technology Officer Mark Day, and our Chief Medical Officer, Chief Scientific Officer, and Executive Vice President of Advanced Technologies, Mintu Turakhia, as defendants.

On October 7, 2024, a second amended complaint was filed against the defendants to include events from the recent FDA inspections, but otherwise included the same claims under the Exchange Act.

On December 10, 2024, the defendants filed a motion to dismiss.

Our board members and certain of our current and former executives were named as defendants in two complaints filed as stockholder derivative actions in the United States District Court for the District of Delaware and the United States District Court for the Northern District of California, respectively.

We are named as a nominal defendant in both complaints.

The cases make similar allegations to those in the securities class action complaint described above and both cases have both been stayed pending the resolution of motion to dismiss briefing in the securities class action.

W e believe the above securities class action and derivative lawsuits to be without merit and plan to continue to defend ourselves vigorously.

On March 26, 2021, we received a grand jury subpoena from the U.S.

On June 3, 2025, the Court granted in part the defendants’ motion to dismiss, including the dismissal of all individual defendants except for Mr.

On November 3, 2025, the plaintiff filed a motion to certify the case as a class action, which the defendants later opposed by motion.

Discovery is ongoing.

Our board members and certain of our current executives and former executives of iRhythm Technologies were named as defendants in two complaints filed as stockholder derivative actions in the United States District Court for the District of Delaware and the United States District Court for the Northern District of California, respectively.

iRhythm Technologies is named as a nominal defendant in both complaints.

The cases make similar allegations to those in the securities class action complaint described above and both derivative cases have been stayed pending the resolution of the securities class action.

We believe the above securities class action and derivative lawsuits to be without merit and plan to continue to defend iRhythm Technologies vigorously.

On March 26, 2021, iRhythm Technologies received a grand jury subpoena from the U.S.

Attorney’s Office for the Northern District of California requesting information related to communications with the Food and Drug Administration and our products and services.

On September 13, 2021, we received a second subpoena requesting additional information.

On April 4, 2023, we received a Subpoena Duces Tecum from the Consumer Protection Branch, Civil Division of the U.S.

Department of Justice (the “DOJ”), requesting production of various documents regarding our products and services.

On September 13, 2021, iRhythm Technologies received a second subpoena requesting additional information.

On April 4, 2023, iRhythm Technologies received a Subpoena Duces Tecum from the Consumer Protection Branch, Civil Division of the U.S.

Department of Justice (the “DOJ”), requesting production of various documents regarding iRhythm Technologies' products and services.

We are cooperating fully on these matters.

On July 1, 2024, the DOJ filed with the United States District Court for the Northern District of California a Petition for Order to Show Cause and Application for Enforcement with respect to the production of certain documentary materials which we assert are protected by legal privileges.

We defended our privilege assertions over such materials in our response to the DOJ’s petition.

The matter has been briefed, and oral argument is scheduled for March 6, 2025.

On February 20, 2024, Welch Allyn, Inc.

(“Welch Allyn”), a subsidiary of Hill-Rom Holdings, Inc.

now part of Baxter International, Inc., filed a lawsuit against us in the United States District Court for the District of Delaware, alleging that our Zio devices infringe certain of its patents and that the Company’s infringement was willful.

We filed a motion to dismiss Welch Allyn’s willful infringement claims on April 11, 2024.

Welch Allyn filed an amended complaint on April 24, 2024 that continued to allege that our Zio devices infringe certain of its patents and that our infringement was willful.

We filed a motion to dismiss Welch Allyn’s willful infringement allegations found in the amended complaint on May 22, 2024 and a hearing on the motion to dismiss was held on January 28, 2025.

After hearing arguments, the Court granted our motion and the willful infringement claims in the amended complaint were dismissed without prejudice.

Welch Allyn filed a second amended complaint adding additional patent claims on February 14, 2025.

The Company is preparing to file a response to the allegations found in the second amended complaint no later than March 21, 2025.

On July 1, 2024, the DOJ filed with the United States District Court for the Northern District of California a Petition for Order to Show Cause and Application for Enforcement against iRhythm Technologies with respect to the production of certain documentary materials which iRhythm Technologies asserts are protected by legal privileges.

On May 30, 2025, following a hearing on the issue, the District Court ordered iRhythm Technologies to disclose certain of the documents, finding that iRhythm Technologies had waived its asserted legal privileges.

We have appealed the District Court's order to the Ninth Circuit Court of Appeals.

On July 17, 2025, the Ninth Circuit Court of Appeals stayed the District Court's production order until the appeal is resolved.

Both parties submitted initial briefing on the merits, and iRhythm Technologies' reply brief to the government is due in late February 2026.

We intend to continue to defend iRhythm Technologies' privilege assertions over the documents at issue.

Regardless of the outcome of the appeal or the potential disclosure of the documents at issue, it is not clear what, if any, action the DOJ may take following resolution of the dispute over legal privileges.

On December 12, 2025, we received a civil investigative demand from DOJ’s Civil Division’s Commercial Litigation Branch seeking information and documents related to Zio AT and our associated claims for reimbursement.

We have cooperated, and are continuing to cooperate, fully in connection with these matters.

On February 20, 2024, Welch Allyn filed a complaint against iRhythm Technologies in the United States District Court for the District of Delaware, which was amended on April 24, 2024, alleging that its Zio devices infringe certain of Welch Allyn's patents and that its infringement was willful.

Thereafter, iRhythm Technologies successfully petitioned the District Court to dismiss the willful infringement claims without prejudice.

On February 14, 2025, Welch Allyn filed a second amended complaint adding additional patent claims.

On March 21, 2025, iRhythm Technologies filed a response to the allegations found in the second amended complaint, denying all allegations of patent infringement and asserting defenses including patent invalidity.

On October 14, 2025, Welch Allyn filed a third amended complaint adding back claims for willful infringement.

On October 28, 2025, iRhythm Technologies filed a motion to dismiss the willful infringement claims, and that motion remains pending.

On December 23, 2024, iRhythm Technologies filed a petition with the USPTO seeking Inter Partes Review ("IPR") of the Welch Allyn patents asserted in the original complaint.

The IPR petitions became subject to a new consideration for “discretionary denial” of IPRs first announced by the USPTO after iRhythm Technologies filed its petitions.

Under this new basis, iRhythm Technologies' IPRs were denied institution.

iRhythm Technologies filed a Petition for Director review, seeking to vacate the denial in July 2025, but the Petition was denied.

iRhythm Technologies subsequently filed for Ex Parte Reexamination on four of the Welch Allyn patents being asserted, and the USPTO instituted re-examination of those four patents on January 20, 2026.

Welch Allyn seeks money damages and attorneys’ fees.

We believe this lawsuit is without merit and plan to defend ourselves vigorously.

On December 10, 2024, Bardy Diagnostics, Inc.

(“BardyDx”), a subsidiary of Hill-Rom Holdings, Inc.

now part of Baxter International, Inc., filed a lawsuit against us in the United States District Court for the District of Delaware, alleging that our Zio Monitor patch infringes one of its patents.

On December 26, 2024, BardyDx filed an amended complaint alleging that the Company's Zio Monitor patch infringes two of its patents.

We are preparing to file a response to the allegations found in the amended complaint no later than March 3, 2025.

BardyDx seeks money damages and attorneys’ fees.

We believe this lawsuit is without merit and plan to defend ourselves vigorously.

We believe this lawsuit is without merit and plan to defend iRhythm Technologies vigorously.

On December 10, 2024, BardyDx filed a lawsuit against iRhythm Technologies in the United States District Court for the District of Delaware, alleging that our Zio monitor infringes one of its patents.

On December 26, 2024, BardyDx filed an amended complaint alleging that our Zio monitor infringes two of BardyDx's patents.

On June 11, 2025, BardyDx filed a second amended complaint alleging that our Zio monitor infringes four of BardyDx’s patents.

iRhythm Technologies filed responses to the allegations found in the complaint and the amended complaints, denying all allegations of patent infringement, asserting defenses including patent invalidity, and asserting patent infringement counterclaims, which allege that BardyDx’s Carnation Ambulatory Monitor patch infringes five of the Company's patents.

BardyDx filed an answer to iRhythm Technologies' counterclaims and filed counterclaims for declaratory judgment for non-infringement and invalidity of the patents asserted by iRhythm Technologies.

On September 5, 2025, iRhythm Technologies filed a motion for leave to amend its counterclaims to allege infringement of two additional patents, and that motion remains pending.

On January 22, 2026, BardyDx filed a motion to amend its pleadings to assert inequitable conduct with respect to two patents of iRhythm Technologies, and that motion also remains pending.

Both parties seek money damages and attorneys’ fees for the alleged infringement of their patents.

We believe BardyDx’s allegations of patent infringement are without merit and plan to defend iRhythm Technologies vigorously.

At this time, we are unable to predict the eventual scope, duration, or outcome of the aforementioned proceedings.

3 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings